Melane Sampson, Author at BioTuesdays

Feature

Mauna Kea launches groundbreaking food-related IBS detection and treatment program

Mauna Kea Technologies (Euronext Growth:ALMKT), inventor of the world’s first and only real-time in vivo cellular imaging platform, Cellvizio, designed to deliver high-magnification visualization of cellular structures...

August 6, 2024

Developments

BioResorative’s Chief Scientist named section editor of top-tier Journal of Translational Medicine

BioRestorative Therapies (NASDAQ:BTRX) announced that Francisco Silva, the company’s chief scientist and vice president of research and development, has been appointed section editor of the newly launched Regenerative...

July 23, 2024

Developments

Anebulo announces NIDA grant for investigational treatment of acute cannabis-induced toxicities in children

Anebulo Pharmaceuticals (NASDAQ:ANEB) has been awarded the first tranche of a two-year, $1.9 million NIDA grant to develop intravenous selonabant for treating acute cannabis-induced toxicity, including CNS depression in...

July 22, 2024

Executive Moves

Sernova appoints Jonathan Rigby as executive chairman

Sernova (TSX:SVA; OTCQB:SEOVF; FSE/XETRA:PSH) has named Jonathan Rigby as executive chairman, effective immediately. Mr. Rigby, previously a director with the company, replaces chairman Brett Whalen, who has resigned...

July 18, 2024

Developments

Clearmind files additional U.S. patent application for MEAI to treat obesity

Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced it has filed an additional patent application with the USPTO for the novel proprietary composition of its MEAI compound for treating metabolic syndrome and obesity...

July 16, 2024

Developments

Alto Neuroscience announces Phase 2b enrollment completion in MDD study

Alto Neuroscience (NYSE:ANRO) announced the completion of enrollment in its Phase 2b study evaluating ALTO-100 in 300 adults with major depressive disorder (MDD) across 34 U.S. sites. The randomized, double-blind...

July 16, 2024

Feature

BerGenBio pioneering cutting-edge AXL therapies to fight aggressive diseases

BerGenBio (OSE:BGBIO) is developing a pipeline of transformative drugs targeting AXL as a cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections.

July 16, 2024

Developments

CMS unveils proposed reimbursement for TULSA to treat prostate disease

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that the U.S. Centers for Medicare and Medicaid Services has issued proposed rules establishing, for the first time, a Category 1 CPT code for the Transurethral...

July 12, 2024

Developments

Rainhouse spotlights CNN reveal on injection cartridge supply issues impacting weight-loss drug shortages

Rainhouse Manufacturing Canada, a well-established North American CNC machining and manufacturing company, emphasized a recent CNN interview with Dr. Sanjay Gupta, which uncovered the real cause of weight-loss drug...

July 12, 2024

Developments

Exscientia launches AWS AI-powered platform to advance drug discovery

Exscientia plc (NASDAQ:EXAI) announced its use of Amazon Web Services (AWS) artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation. Exscientia’s...

July 10, 2024

Author - Melane Sampson

Mauna Kea launches groundbreaking food-related IBS detection and treatment program

BioResorative’s Chief Scientist named section editor of top-tier Journal of Translational Medicine

Anebulo announces NIDA grant for investigational treatment of acute cannabis-induced toxicities in children

Sernova appoints Jonathan Rigby as executive chairman

Clearmind files additional U.S. patent application for MEAI to treat obesity

Alto Neuroscience announces Phase 2b enrollment completion in MDD study

BerGenBio pioneering cutting-edge AXL therapies to fight aggressive diseases

CMS unveils proposed reimbursement for TULSA to treat prostate disease

Rainhouse spotlights CNN reveal on injection cartridge supply issues impacting weight-loss drug shortages

Exscientia launches AWS AI-powered platform to advance drug discovery

General

More